Shurygina Anna-Polina, Shuklina Marina, Ozhereleva Olga, Romanovskaya-Romanko Ekaterina, Kovaleva Sofia, Egorov Andrej, Lioznov Dmitry, Stukova Marina
Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, Saint-Petersburg 197022, Russia.
Vaccines (Basel). 2025 Jan 10;13(1):58. doi: 10.3390/vaccines13010058.
Influenza viruses with truncated NS1 proteins show promise as viral vectors and candidates for mucosal universal influenza vaccines. These mutant NS1 viruses, which lack the N-terminal half of the NS1 protein (124 a.a.), are unable to antagonise the innate immune response. This creates a self-adjuvant effect enhancing heterologous protection by inducing a robust CD8+ T-cell response together with immunoregulatory mechanisms. However, the effects of NS1 modifications on T-follicular helper (Tfh) and B-cell responses remain less understood.
C57bl/6 mice were immunised intranasally with 10 μL of either an influenza virus containing a truncated NS1 protein (PR8/NS124), a cold-adapted influenza virus with a full-length NS1 (caPR8/NSfull), or a wild-type virus (PR8/NSfull). Immune responses were assessed on days 8 and 28 post-immunisation by flow cytometry, ELISA, and HAI assay.
In this study, we demonstrate that intranasal immunisation with PR8/NS124 significantly increases tissue-resident CD4+ and CD8+ T cells in the lungs and activates Tfh cells in regional lymph nodes as early as day 8 post-immunisation. These effects are not observed in mice immunised with caPR8/NSfull or PR8/NSfull. Notably, PR8/NS124 immunisation also leads to the development of inducible bronchus-associated lymphoid tissue (iBALT) in the lungs by day 28, characterised by the presence of antigen-specific Tfh cells and GL7+Fas+ germinal centre B cells.
Our findings further underscore the potential of NS1-truncated influenza viruses to drive robust mucosal immune responses and enhance vaccine efficacy.
具有截短型NS1蛋白的流感病毒有望成为病毒载体及黏膜通用流感疫苗的候选物。这些突变的NS1病毒缺乏NS1蛋白的N端一半(124个氨基酸),无法拮抗先天免疫反应。这产生了一种自我佐剂效应,通过诱导强烈的CD8+ T细胞反应以及免疫调节机制来增强异源保护作用。然而,NS1修饰对滤泡辅助性T细胞(Tfh)和B细胞反应的影响仍不太清楚。
用10 μL含有截短型NS1蛋白的流感病毒(PR8/NS124)、具有全长NS1的冷适应流感病毒(caPR8/NSfull)或野生型病毒(PR8/NSfull)经鼻免疫C57bl/6小鼠。在免疫后第8天和第28天通过流式细胞术、酶联免疫吸附测定(ELISA)和血凝抑制(HAI)试验评估免疫反应。
在本研究中,我们证明用PR8/NS124经鼻免疫可显著增加肺组织驻留的CD4+和CD8+ T细胞,并早在免疫后第8天就激活局部淋巴结中的Tfh细胞。在用caPR8/NSfull或PR8/NSfull免疫的小鼠中未观察到这些效应。值得注意的是,到第28天时,用PR8/NS124免疫还会导致肺中诱导性支气管相关淋巴组织(iBALT)的形成,其特征是存在抗原特异性Tfh细胞和GL7+Fas+生发中心B细胞。
我们的研究结果进一步强调了截短NS1的流感病毒驱动强大黏膜免疫反应并提高疫苗效力的潜力。